CN114276328B - Compound as small molecule immunosuppressant, preparation method and application thereof - Google Patents

Compound as small molecule immunosuppressant, preparation method and application thereof Download PDF

Info

Publication number
CN114276328B
CN114276328B CN202011041992.4A CN202011041992A CN114276328B CN 114276328 B CN114276328 B CN 114276328B CN 202011041992 A CN202011041992 A CN 202011041992A CN 114276328 B CN114276328 B CN 114276328B
Authority
CN
China
Prior art keywords
methyl
methoxy
biphenyl
dimethoxypyrimidin
morpholinopropoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011041992.4A
Other languages
Chinese (zh)
Other versions
CN114276328A (en
Inventor
孙效华
尹大伟
杨阳
刘洋
陈庆广
王静
王静然
杨红振
胡怀忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Konruns Pharmaceutical Co Ltd
Original Assignee
Beijing Konruns Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Konruns Pharmaceutical Co Ltd filed Critical Beijing Konruns Pharmaceutical Co Ltd
Priority to CN202011041992.4A priority Critical patent/CN114276328B/en
Publication of CN114276328A publication Critical patent/CN114276328A/en
Application granted granted Critical
Publication of CN114276328B publication Critical patent/CN114276328B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a compound serving as a small molecule immunosuppressant, a preparation method and application thereof. The invention specifically discloses a compound shown in a formula I or pharmaceutically acceptable salts, prodrugs, metabolites, isotopic derivatives and solvates thereof. The compound of the present invention is a pyrimidine ring-containing compound that acts on the PD-1/PD-L1 signaling pathway and is relevant to the treatment of neoplastic diseases and other immune disorders. The compound of the invention can improve the drug effect and reduce the side effect of the drug. The invention also provides a preparation method of the compound and application of the compound in treating diseases related to PD-1/PD-L1 signal paths.

Description

Compound as small molecule immunosuppressant, preparation method and application thereof
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a compound for treating diseases related to PD-1/PD-L1 signal paths. The invention also relates to a preparation method of the compound and application thereof in treating cancers or immune diseases.
Background
Programmed death receptor 1 (Programmed Cell Death Protein, PD-1), a type I transmembrane protein consisting of 268 amino acids, is an immune co-suppressor molecule that is specifically expressed only on T cells. In normal organisms, PD-1 acts as a negative regulator of T cell proliferation, playing an important role in maintaining immune tolerance in the body. The programmed death receptor 1 ligand (PD-L1) is also a type I transmembrane protein, highly selectively expressed in tumor cells. When T cell receptor is activated, PD-1 and PD-L1 are combined, and are expressed in tumor infiltration lymphocytes in effector stage, so that the activity of the T lymphocytes is inhibited. When a tumor occurs, the PD-1/PD-L1 signaling pathway can inhibit the immune response of T cells so as to promote the occurrence of tumor immune escape. Studies show that blocking the PD-1/PD-L1 signal pathway can enhance the effect T lymphocytes to reach tumor sites, reduce the inhibition of regulatory T lymphocytes at the tumor sites and enhance the endogenous tumor immune effect of organisms, so that PD-1/PD-L1 has become an important drug target for tumor immunotherapy.
Several drugs have been marketed for the monoclonal PD-1/PD-L1 inhibitors, but no small molecule inhibitors have been marketed at present. Compared with the monoclonal antibody, the small molecular medicine has the advantages of flexible administration mode (oral administration), short half-life, stable property, high exposure, low price, no side effect related to immune rejection reaction and the like, so the development of the small molecular immunosuppressant is urgent.
Disclosure of Invention
The invention provides a novel pyrimidine ring-containing compound used as a PD-1/PD-L1 inhibitor, which has a structure shown in a formula I. The compounds of the present invention and pharmaceutically acceptable salts, prodrugs, isotopic derivatives, and solvates thereof, and pharmaceutical compositions containing the compounds, are useful in treating neoplastic diseases associated with inhibition of PD-1/PD-L1 signaling pathway.
The compounds of the present invention have the structure shown in formula I:
wherein X is selected from Br, cl and F;
y is selected from methyl, ethyl, isopropyl, cyclopropyl, cl, F and H;
R 1 and R is 2 Independently selected from H, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituents selected from C1-C6 alkyl, C1-C6 alkoxy;
R 1 And R is 2 Optionally together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-7 membered heterocyclic group;
n＝1、2、3；
R 3 selected from hydrogen, C1-C6 alkyl, substituted or unsubstituted 6-10 membered aryl, substituted or unsubstituted 6-10 membered cycloalkyl, substituted or unsubstituted 6-10 membered heterocycloalkyl, substituted or unsubstituted 5-7 membered heteroaryl;
R 4 and R is R 5 Independently selected from hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C1-C8 alkoxy, substituted or unsubstituted 3-6 membered cycloalkyl, and amide groups;
R 4 and R is 5 Optionally together with the nitrogen atom to which they are attached form a substituted or unsubstituted 4-7 membered heterocyclic ringA base;
R 1 、R 2 、R 1 and R is 2 4-7 membered heterocyclic ring, together with the nitrogen atom to which it is attached, R 4 、R 5 、R 4 And R is 5 4-7 membered heterocyclic ring which is formed together with the nitrogen atom to which it is attached, wherein the substituent of the 4-7 membered heterocyclic ring formed is at least one of 1-4C 1-C6 alkyl groups, 3-6 cycloalkyl groups, 3-6 heterocycloalkyl groups, hydroxyl groups, carboxyl groups, amino groups, nitrile groups, halogen groups, trifluoromethyl groups, and nitro groups; the 3-6 membered heterocycloalkyl or heteroaryl contains 1-3 heteroatoms selected from N, O, S.
In the compound disclosed by the invention, the substituent group of the biphenyl in the molecular structure of the compound can increase the conjugated system of the whole molecule, has a certain steric hindrance effect and can increase the directionality of the molecule, so that the compound can be better embedded with dimers formed by two PD-L1. Meanwhile, the substituent groups led out from the left side structure of the molecule can increase the solubility and the membrane permeability of the whole molecule, thereby increasing the drug property of the molecule. When the compound disclosed by the invention is embedded with the PD-L1 dimer, the PD-L1 can not be combined with the PD-1 any more, so that the PD-L1 can be identified and killed by T cells, and then the high expression of the PD-L1 in tumor cells is inhibited, and the purpose of treating tumor diseases is achieved.
More specifically, in the compounds of the invention, Y is selected from the group consisting of methyl, ethyl, isopropyl, cyclopropyl, cl, F, H, these groups being smaller in volume or shorter in chain length. Mainly considering the course of the study, the inventors found that when Y selects larger or longer groups, the activity decreases significantly. The main reason is that the activity of the compounds of the invention on PD-L1 is related to Y and X in the molecule. The angle formed by the two benzene rings of a biphenyl group is related to the groups X and Y. When two benzene rings of biphenyl groups in the compound form an included angle smaller than 45 degrees, the compound has higher activity, and when Y is too large or too long, the included angle exceeds 45 degrees, instead, the directivity is reduced, and the activity of the compound is reduced.
In the above compound of formula I, the value of n is preferably not more than 3. The carbon chain n is not suitable for too long or too short, and the value of n is preferably 3. The presence of this side chain is on the one hand related to physicochemical properties such as solubility, fat-solubility etc. When n is less than or equal to 3, the compound can be made to have good physicochemical properties. When N is more than 3, the side chain is too long, resulting in a decrease in solubility and lipid solubility of the compound. On the other hand, the presence of this side chain is related to the ability of the compound to bind to the target. If the carbon chain is too long, the compound will not make effective contact with the target.
In the compound shown in the formula I, R 1 4-7 membered heterocyclic ring which may be independently co-formed with the nitrogen atom to which it is attached, R 2 Or 4-7 membered heterocyclic ring which may be formed separately from the nitrogen atom to which it is attached. Further, R is 1 And R is 2 A 4-7 membered heterocyclic ring which may be simultaneously co-formed with the attached nitrogen atom.
In addition, R 1 And R is 2 Nor should the volume be too large. R is R 1 And R is 2 Excessive volume or excessive chain length results in included angles exceeding 45 degrees, resulting in reduced activity of the compound.
Similarly, R 4 、R 5 、R 4 And R is 5 4-7 membered heterocyclic ring R, together with the nitrogen atom to which it is attached 4 、R 5 、R 4 And R is 5 A 4-7 membered heterocyclic ring which is co-formed with the nitrogen atom to which it is attached.
In the compounds of the invention of the formula I, the radicals R 1 、R 2 、R 4 、R 5 Cyclization can limit the conformation of the molecule, moderately increase rigidity, and is beneficial for increasing the directionality of the molecule. The chain substituent has larger activity, good flexibility and stronger fat solubility, but the directivity is reduced, and the metabolic site is increased. R is R 1 、R 2 、R 4 、R 5 In combination with other groups of formula I, different molecules of the compound can be specifically designed.
The compound according to the invention or a pharmaceutically acceptable salt, prodrug, metabolite, isotopic derivative, solvate thereof,
Wherein R is 1 And R is 2 Each is preferably selected from methyl, ethyl, isopropyl, cyclopropyl, phenyl, pyridinyl;
alternatively, R 1 And R is R 2 A 4-7 membered heterocyclic group together with the nitrogen atom to which it is attached, wherein R 1 And R is 2 The 4-7 membered heterocyclic group which is co-formed with the nitrogen atom to which it is attached is preferably selected from the group consisting of:
R 3 preferably selected from one of hydrogen, pyridyl, nitrile group substituted phenyl.
In the above 4-7 membered heterocyclic group, for 4-hydroxypiperidine, the polarity and solubility of the compound molecule are increased due to the presence of the hydroxyl group.
For containing R as described herein 1 And R is R 2 The compound of the group, the small molecular compound forms dimerization with two molecules of PD-L1, the small molecular compound is embedded in the middle of the dimer, so that the embedding of the compound and the PD-L1 is stronger, the activity of the compound is improved, and meanwhile, R 1 And R is R 2 Chain or cyclic substituents formed, especially at R 1 Or R is 2 The compound has better ability to form hydrogen bonds with amino acids on targets under the condition of shorter chain length or non-aromatic cyclic group formation, thereby being beneficial to improving the activity of the compound and improving the patentability of the molecule.
The compound according to the invention or a pharmaceutically acceptable salt, prodrug, metabolite, isotopic derivative, solvate thereof,
Wherein R is 4 And R is 5 Identical or different, R 4 And R is 5 Together with the attached nitrogen atom form a substituted or unsubstituted 4-7 membered heterocyclic group; wherein R is 4 And R is 5 The 4-to 7-membered heterocyclic group which constitutes a substituent(s) together with the nitrogen atom to which it is attached is preferably selected from 1-piperidyl, 1-pyrrolidinyl, 4-methyl-1-piperidyl, 1-cyclobutylamino and 1-cyclopentylamino.
Preferably, R 4 And R is 5 Independently selected from amide groups, wherein the amide groups are selected from-R 6 -C(＝O)-NH-R 7 or-R 6 -NH-C(＝O)R 7 ，R 6 And R is 7 Each independently is a C1-C5 alkyl group.
R 4 Or R is 5 Preferably with a shorter chain length or with cyclic groups. These groups have a better ability to form hydrogen bonds with amino acids on the target, helping to increase the activity of the compound.
The compound is selected from any one of the following compounds:
(S) -1- ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) piperidine-2-carboxylic acid
((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-serine
(2S, 4R) -1- ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid
((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-alanine
(S) -1- ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) piperidine-2-carboxylic acid
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-serine
(2S, 4R) -1- ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-alanine
((2- ((2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-bromo-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphen yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphen yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-fluoro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-fluoro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-fluoro-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphen yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-2 ' -methyl-3 ' - (2-morpholinoethoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-2 ' -methyl-3 ' - (3-piperidin-1-yl) propoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-2 ' -methyl-3 ' - (3-piperidin-1-yl) ethoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-3 '- (3-piperidinepropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxy pyrimidin-5-yl) methyl) -L-proline
((2- ((2, 2' -dichloro-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy-4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-3 ' - (3- (dimethylamino) propoxy) -2' -methyl- [1,1' -biphen-yl ] -3-yl) methoxy-4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-2 ' -ethyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-2 ' -isopropyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-2 ' -cyclopropyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4- ((3-cyanobenzyl) oxy) -6-methoxypyrimidin-5-yl) methyl) -L-proline
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4-methoxy-6- (pyridin-3-ylmethoxy) pyrimidin-5-yl) methyl) -L-proline
(2S, 4R) -1- ((2- ((2-bromo- [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid
((2- ((2-chloro-2 ' -butyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The present invention also provides a process for preparing a compound of formula I, wherein the process comprises the following reaction scheme:
the method comprises the following steps:
(1) Dissolving SM1 and SM2 in a solvent 1, adding an alkaline reagent, and reacting at a temperature ranging from room temperature to 70 ℃ to obtain a compound C01;
(2) Dissolving a compound C01 in a solvent 2, adding an alkaline reagent and a palladium metal catalyst, and reacting at a temperature range of 70-120 ℃ to obtain a compound C02;
(3) Dissolving a compound C02 and SM3 in a solvent 3, adding an alkaline reagent and a palladium metal catalyst, and reacting at a temperature range of 70-120 ℃ to obtain a compound C03;
(4) C03 and SM4 are dissolved in a solvent 4 to carry out reductive amination reaction, and the compound of the formula I is obtained.
Preferably, in step (1), the solvent 1 is selected from one or more of tetrahydrofuran, DMSO, DMF, acetonitrile; the alkaline reagent is selected from one or more of cesium carbonate, potassium carbonate, sodium carbonate, potassium tert-butoxide and sodium tert-butoxide;
preferably, in step (2), the solvent 2 is selected from one or more of 1, 4-dioxane, toluene, benzene; the alkaline reagent is selected from one or more of potassium acetate, cesium carbonate, potassium carbonate and sodium carbonate; the palladium metal catalyst is selected from Pd (PPh) 3 ) 4 、Pd(dppf)Cl 2 Palladium acetate, pd 2 (dba) 3 One or more of the following;
preferably, in step (3), the solvent 3 is selected from one or more of 1, 4-dioxane, toluene and water; the alkaline reagent is selected from one or more of cesium carbonate, potassium carbonate, sodium carbonate, potassium tert-butoxide and sodium tert-butoxide; the palladium metal catalyst is selected from Pd (PPh) 3 ) 4 、Pd(dppf)Cl 2 Palladium acetate, pd 2 (dba) 3 One or more of the following;
preferably, in step (4), the solvent 4 is selected from one or more of tetrahydrofuran, DMSO, DMF, acetonitrile, methanol, dichloromethane; the reducing agent for the reductive amination reaction is selected from NaBH 3 CN, sodium triacetoxyborohydride, sodium borohydride.
The invention also provides a pharmaceutical composition comprising the compound or a pharmaceutically salt of the compound or a solvate of the compound, and a pharmaceutically acceptable carrier.
In order to adapt to different administration modes, the pharmaceutical composition of the invention can be prepared into various dosage forms. Preferably, the pharmaceutical composition of the present invention is in the form of an oral preparation or an injection.
The compound of the invention is a PD-1/PD-L1 signal path inhibitor, and can be applied to treatment of diseases related to PD-1/PD-L1 signal paths after being prepared into various preparations, wherein the diseases can be malignant tumors or cancers, and can also be immune diseases.
Alternatively, the cancer is selected from skin cancer, lung cancer, hematological tumor, breast cancer, glioma, digestive system tumor, reproductive system tumor, lymphoma, nervous system tumor, head and neck cancer; the immune disease is selected from diabetes, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus and dermatitis.
Accordingly, the present invention also provides a method of treating cancer or an immune disorder, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of the present invention.
Within the meaning of the present invention, the terms used are defined as follows:
"halogen" means F, cl, br, I.
"C1-C6 alkyl" refers to an alkyl chain having 1 to 6 carbon atoms, which may be straight or branched. For example: methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and the like.
"C1-C8 alkoxy" means an alkyl chain having 1 to 8 carbon atoms, which may be straight or branched, wherein at least one carbon atom is replaced by an oxygen atom.
"6-10 membered aryl" means aryl having 6-10 carbon atoms, e.g., phenyl, naphthyl. The hydrogen atom on a carbon atom in the ring may be substituted with a specified substituent.
"3-6 membered cycloalkyl", "6-10 membered cycloalkyl" means a saturated carbocyclic ring having 3 to 6 and 6 to 10 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, respectively, the hydrogen atom on the carbon atom in the ring being optionally substituted by a specified substituent.
"6-10 membered heteroaryl" refers to an aryl group having 6-10 atoms, wherein 1-3 carbon atoms in the ring may be replaced by N, O, S. Such as quinolinyl, isoquinolinyl, pyridinyl, benzofuranyl, and the like.
"4-7 membered heterocyclic ring" means a heterocyclic ring having 4 to 7 atoms, such as a tetrahydropyrrole ring, piperidine ring, piperazine ring, and the like.
"3-6 membered heterocycloalkyl" means that the carbocycle having 3 to 6 carbon atoms contains at least one N, O, S heteroatom of N, O, S heteroatoms forming a heterocyclic group.
"prodrug" refers to a derivative that is converted to a compound of the present invention by an enzymatic oxidation, reduction, hydrolysis, or other reaction in vivo under physiological conditions.
"metabolite" means all molecules derived from the compounds of the invention produced in a cell or organism, preferably a human.
"isotopic derivative" means a compound comprising one or more isotopic atoms in non-natural proportions in the structure constituting the compound of the present invention. Such as deuterium (2H or D), carbon-13 (13C), nitrogen-15 (15N).
"solvate" means a form of a solvent complex formed by the physical association of a compound of the invention with a solvent molecule. The physical bonding comprises hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, tetrahydrofuran, ethyl acetate, acetonitrile, and the like. The compounds of formula I may be prepared in crystalline form and may be in solvate form (including hydrate form).
Pharmaceutically acceptable salts of the compounds of formula I contain one or more basic or acidic groups, in particular pharmaceutically usable salts thereof. Such as alkali metal salts, alkaline earth metal salts, ammonium salts. More precisely, it may be a sodium salt, potassium salt, calcium salt, magnesium salt or an organic amine such as ethylamine, ethanolamine, triethylamine or an amino acid salt. The compounds of the present invention may form protonated compounds of formula I with inorganic or organic acids, examples of which include hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, methanesulfonic acid, lactic acid, malic acid, maleic acid, tartaric acid, and the like, as well as other acids known to those skilled in the art.
"pharmaceutical composition" when used as a medicament means a composition of a compound of formula I according to the invention, and salts, isotopic derivatives, metabolites, prodrugs, solvates and other biologically active substances, with or without, and which can be used for the treatment or prophylaxis of diseases associated with the PD1/PDL-1 signalling pathway, such as solid tumors, hematological tumors and the like.
Drawings
FIG. 1 is a general structure of a compound of formula I according to the present invention.
Detailed Description
The present invention will be described in detail with reference to the following examples.
Example 1
(S) -1- ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) piperidine-2-carboxylic acid
The structural formula of the compound is as follows:
the synthetic route is as follows:
the synthesis method comprises the following steps:
preparation of 4- (3- (3-bromo-2-methylphenoxy) propyl) morpholine:
to the reaction flask was added 3-bromo-2-methylphenol (1.61 g,1 eq), 4- (3-chloropropyl) morpholine (1.55 g,1.1 eq), acetonitrile (40 mL), potassium carbonate (3.56 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (150 mL), extracted with ethyl acetate (60 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and crude silica gel column chromatographed to give 4- (3- (3-bromo-2-methylphenoxy) propyl) morpholine (2.06 g, yield: 76%). MS [. Sup.M+1 ] +:314.1.
Preparation of 4- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) morpholine:
4- (3- (3-bromo-2-methylphenoxy) propyl) morpholine (2.06 g,1 eq), pinacol biborate (3.33 g,2 eq), potassium acetate (1.29 g,2 eq), pd (dppf) Cl were added to the reaction flask 2 (0.24 g,0.05 eq) and 1, 4-dioxane (50 mL). The temperature was raised to 90℃under nitrogen protection, and the reaction was stirred for two hours LCMS to characterize the reaction was completeThe reaction was quenched by the addition of water (350 mL), extracted with ethyl acetate (100 mL. Times.3), the combined organic phases were washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and the crude product was chromatographed on silica gel to give 4- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) morpholine (1.28 g, yield: 54%). MS [. Sup.M+1 ]]+:362.2.
Preparation of methyl 2-bromo-3-iodobenzoate:
to the reaction flask were added methyl 3-amino-2-bromobenzoate (25.1 g,1 eq), acetonitrile (250 mL) and water (400 mL), and concentrated hydrochloric acid (40 mL) was added to the above system with stirring. After stirring at room temperature for 10min, the temperature was lowered to 0℃and a solution of sodium nitrite (15.1 g,2 eq) in water (200 mL) was added dropwise with stirring. After stirring at 0℃for 30min, an aqueous potassium iodide solution (21.8 g,1.2eq,200mL of water) was added dropwise to the system, and the mixture was stirred at room temperature for 3 hours. LCMS indicated the reaction was complete. Ethyl acetate (300 ml x 3) and the organic phases were combined and washed once with saturated brine, dried over anhydrous sodium sulfate, suction filtered, concentrated, and crude product was chromatographed on silica gel to give methyl 2-bromo-3-iodobenzoate (34 g, yield: 92%).
Preparation of methyl-2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-carboxylic acid ester:
4- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) morpholine (2.56 g,1.2 eq), methyl 2-bromo-3-iodobenzoate (2.01 g,1 eq), potassium carbonate (2.44 g,3 eq), pd (dppf) Cl 2 (0.22 g,0.05 eq), toluene (100 mL), water (10 mL) and methanol (10 mL). Heating to 90 ℃ under the protection of nitrogen, stirring and reacting for 16 hours, LCMS characterizing the reaction to be complete, stopping the reaction, adding water (700 mL) to quench the system, extracting ethyl acetate (200 mL of 3), combining organic phases and washing the organic phases with saturated saline once, drying with anhydrous sodium sulfate, suction filtering, concentrating, and obtaining methyl-2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl by crude silica gel column chromatography]3-Formate (0.93 g, yield: 36%). MS [. Sup.M+1 ]]+:448.1/450.1.
Preparation of (2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methanol:
into a reaction flask was charged methyl-2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenolBase group]3-Formate (0.93 g,1 eq), freshly distilled tetrahydrofuran (50 mL), and LiAlH was added in portions at 5 ℃ 4 (0.16 g,2 eq) stirred at room temperature for 30min, TLC characterised by complete reaction, slow dropwise addition of the reaction system to saturated aqueous NH4Cl solution for quenching the reaction, extraction with ethyl acetate (100 mL. 3), combining the organic phases and washing once with saturated brine, drying over anhydrous sodium sulphate, suction filtration and concentration to give 2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ]-3-yl) methanol (0.74 g, yield: 85%) of crude product. The crude product is directly used for the next reaction without any purification treatment. MS [. Sup.M+1 ]]+:420.1/422.1.
Preparation of 2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethylpyrimidine-5-carbaldehyde:
to the reaction flask was added 2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methanol (0.74, 1 eq), 2-chloro-4, 6-dimethoxypyrimidine (0.54 g,1.5 eq), acetonitrile (50 mL), potassium carbonate (0.73 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (400 mL), extracted with ethyl acetate (150 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and the crude silica gel column chromatographed to give 2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethylpyrimidine-5-carbaldehyde (0.76 g, yield: 74%). MS [ M+1] +:586.2/588.2
Preparation of (S) -1- ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) piperidine-2-carboxylic acid:
2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethylpyrimidine-5-carbaldehyde (86.8 mg,1 eq) and L-2-piperidineic acid (57.3 mg,3 eq) were dissolved in a mixed solvent of DMF (5 mL) and methanol (2 mL), 1 drop of acetic acid was added dropwise with stirring, and after reacting at room temperature for 30min, sodium cyanoborohydride (27.9 mg,3 eq) was added to the system. Stirring overnight at room temperature, LCMS indicated that the reaction was complete, stopping the reaction, adding water (50 mL) to quench the system, extracting with ethyl acetate (20 mL. 3), combining the organic phases and washing once with saturated brine, drying over anhydrous sodium sulfate, suction filtration, concentrating, and purifying the crude product by preparative liquid phase to give (S) -1- ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) piperidine-2-carboxylic acid (29.0 mg, yield: 28%). MS [. Sup.M+1 ] +:699.2/701.2.
1H NMR(400MHz,d 6 -DMSO)δ7.58(m,1H),7.47(t,J＝7.6Hz,1H),7.27–7.18(m,2H),6.99(d,J＝8.0Hz,1H),6.70(d,J＝7.2Hz,1H),5.59–5.46,2H),4.18–3.99(m,2H),3.85(s,6H),3.69–3.62(m,2H),3.61–3.48(m,5H),2.96–2.82(m,2H),2.50–2.43(m,2H),2.40–2.30(m,4H),2.20–2.10(m,1H),1.96–1.80(m,5H),1.68–1.60(m,2H),1.49–1.34(m,3H)。
Example 2
((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
preparation of ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline:
with reference to the synthetic method of reductive amination in example 1, 2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenylyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and L-proline to synthesize (2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :685.2/687.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.61(m,1H),7.47(t,J＝7.6Hz,1H),7.26–7.14(m,2H),6.98(d,J＝8.0Hz,1H),6.68(d,J＝7.4Hz,1H),5.56–5.42(m,2H),4.12–4.00(m,2H),3.94–3.75(m,8H),3.60–3.54(m,4H),3.25–3.07(m,4H),2.49–2.43(m,2H),2.42–2.30(m,4H),2.09–2.00(m,1H),1.95–1.87(m,2H),1.87(s,3H),1.83–1.75(m,1H),1.74–1.55(m,1H)。
Example 3
((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-serine
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
preparation of ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-serine:
with reference to the synthetic method of reductive amination in example 1, 2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenylyl) ]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and L-serine were synthesized as ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-serine. MS [. Sup.M+1 ]] + :631.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.61(m,1H),7.48(t,J＝7.6Hz,1H),7.28–7.17(m,2H),6.99(d,J＝8.2Hz,1H),6.71(d,J＝7.4Hz,1H),5.61–5.43(m,2H),4.18–3.99(m,2H),3.85(s,6H),3.75–3.61(m,2H),3.69–3.62(m,2H),3.61–3.48(m,4H),2.94–2.82(m,1H),2.51–2.43(m,2H),2.42–2.31(m,4H),1.96–1.80(m,5H)。
Example 4
(2S, 4R) -1- ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
preparation of (2 s,4 r) -1- ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid:
with reference to the synthetic method of reductive amination in example 1, 2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenylyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and (2S, 4R) -4-hydroxypyrrole-2-carboxylic acid to synthesize (2S, 4R) -1- ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenol)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid. MS [. Sup.M+1 ]] + :657.3。
1 H NMR(400MHz,d 6 -DMSO)δ7.56(d,J＝6.6Hz,1H),7.47(t,J＝7.6Hz,1H),7.26–7.14(m,2H),6.98(d,J＝8.2Hz,1H),6.68(d,J＝7.6Hz,1H),5.59–5.37(m,2H),4.20–3.99(m,4H),3.88(s,6H),3.73(s,2H),3.61–3.50(m,4H),3.27–3.15(m,2H),2.47–2.42(m,2H),2.39–2.30(m,4H),2.02–1.77(m,7H)。
Example 5
((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-alanine
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
/>
preparation of ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-alanine:
with reference to the synthetic method of reductive amination in example 1, 2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenylyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and L-alanine were synthesized as ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-alanine. MS [. Sup.M+1 ]] + :614.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.59(m,1H),7.49(t,J＝7.6Hz,1H),7.29–7.17(m,2H),7.01(d,J＝8.2Hz,1H),6.72(d,J＝7.4Hz,1H),5.60–5.43(m,2H),4.17–3.98(m,2H),3.86(s,6H),3.69–3.62(m,2H),3.61–3.34(m,5H),2.51–2.43(m,2H),2.42–2.31(m,4H),1.94–1.82(m,5H),1.24(d,J＝6.6HZ,3H)。
Example 6
(S) -1- ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) piperidine-2-carboxylic acid
The structural formula of the compound is as follows:
the synthetic route is as follows:
the synthesis method comprises the following steps:
preparation of 2-chloro-4, 6-dimethoxypyrimidine-5-carbaldehyde:
phosphorus oxychloride (229.2 g,15 eq) was added dropwise to a reaction flask containing DMF (109.2 g,15 eq) in an ice-water bath, stirred for 30min in an ice-water bath, and the mixture was added dropwise to the reaction systemA solution of 2-chloro-4, 6-dimethoxypyrimidine (17.4 g,1 eq) in DMF (200 mL) was added, the temperature was raised to 50℃and the reaction was stirred for two hours. LCMS indicated complete reaction and stopped the reaction. The reaction system was added dropwise to an ice-water bath under stirring, adjusted to neutrality (ph=7) with sodium bicarbonate, filtered with suction, washed twice with water, and the dried crude product was purified by silica gel column chromatography to give preparation of 2-chloro-4, 6-dimethoxypyrimidine-5-carbaldehyde (11.4 g, yield 56%). MS [. Sup.M+1 ] ] + :203.1.
Preparation of 2- ((3-bromo-2-chlorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde:
to the reaction flask was added 3-bromo-2-chlorobenzyl alcohol (2.6 g,1 eq), 2-chloro-4, 6-dimethoxypyrimidine (3.6 g,1.5 eq), acetonitrile (100 mL), potassium carbonate (4.8 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (700 mL), extracted with ethyl acetate (200 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and crude silica gel column chromatographed to give 2- ((3-bromo-2-chlorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (3.4 g, yield: 75%). MS [. Sup.M+1 ] +:389.0.
Preparation of 2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde:
to the reaction flask was added 4- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) morpholine (1.28 g,1.1 eq), 2- ((3-bromo-2-chlorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (1.24 g,1 eq), potassium carbonate (1.32 g,3 eq), pd (dppf) Cl 2 (0.12 g,0.05 eq), toluene (50 mL), water (5 mL) and methanol (5 mL). Heating to 90 ℃ under the protection of nitrogen, stirring and reacting for 16 hours, LCMS (liquid Crystal ms) characterizing the reaction to be complete, stopping the reaction, adding water (350 mL) to quench the system, extracting ethyl acetate (100 mL of 3), combining organic phases and washing the organic phases with saturated common salt once, drying with anhydrous sodium sulfate, suction filtering, concentrating, and obtaining 2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) by crude silica gel column chromatography ]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (0.78 g, yield: 45%). MS [. Sup.M+1 ]]+:542.2.
Preparation of (S) -1- ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) piperidine-2-carboxylic acid:
2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (80.2 mg,1 eq) and L-2-pipecolic acid (57.3 mg,3 eq) were dissolved in a mixed solvent of DMF (5 mL) and methanol (2 mL), 1 drop of acetic acid was added dropwise with stirring, and after reaction at room temperature for 30min, sodium cyanoborohydride (27.9 mg,3 eq) was added to the system. After stirring overnight at room temperature, LCMS indicated that the reaction was complete, the reaction was stopped, the system was quenched with water (50 mL), ethyl acetate (20 mL. 3) was extracted, the organic phases were combined and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and the crude product was purified by preparative liquid phase to give (S) -1- ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) piperidine-2-carboxylic acid (32 mg, yield: 30%). MS: [ M+1] +:655.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.60(dd,J＝7.6,1.3Hz,1H),7.43(t,J＝7.6Hz,1H),7.18-7.27(m,2H),6.99(d,J＝8.2Hz,1H),6.70(d,J＝7.4Hz,1H),5.59–5.46(m,2H),4.11–3.99(m,2H),3.85(s,6H),3.69–3.62(m,2H),3.61–3.48(m,5H),2.96–2.82(m,2H),2.50–2.43(m,2H),2.40–2.30(m,4H),2.20–2.10(m,1H),1.96–1.82(m,5H),1.68–1.60(m,2H),1.49–1.34(m,3H)。
Example 7
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
preparation of ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline:
with reference to the synthetic method of reductive amination in example 6, 2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) was synthesized]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and L-proline to synthesize (2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :641.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.60(d,J＝7.2Hz,1H),7.44(t,J＝7.6Hz,1H),7.31–7.18(m,2H),6.99(d,J＝8.0Hz,1H),6.70(d,J＝7.2Hz,1H),5.52(s,2H),4.10–4.00(m,2H),3.95–3.78(m,8H),3.60–3.50(m,4H),3.20–3.05(m,4H),2.50–2.43(m,2H),2.40–2.30(m,4H),2.04–1.96(m,1H),1.97–1.75(m,6H),1.73–1.55(m,1H)。
Example 8
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-serine
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
preparation of ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-serine:
with reference to the synthetic method of reductive amination in example 6, 2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) was synthesized]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and L-serine were synthesized as ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) ]-3-yl) methoxy) -4, 6-dimethoxy-azotemic acidPyridin-5-yl) methyl) -L-serine. MS [. Sup.M+1 ]] + :631.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.60(dd,J＝7.6,1.3Hz,1H),7.44(t,J＝7.6Hz,1H),7.28–7.17(m,2H),6.99(d,J＝8.2Hz,1H),6.70(d,J＝7.4Hz,1H),5.59-5.47(m,2H),4.12–3.99(m,2H),3.85(s,6H),3.72–3.64(m,2H),3.61–3.47(m,2H),3.61–3.48(m,4H),2.94–2.82(m,1H),2.51–2.43(m,2H),2.42–2.31(m,4H),1.96–1.80(m,5H)。
Example 9
(2S, 4R) -1- ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
preparation of (2 s,4 r) -1- ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid:
with reference to the synthetic method of reductive amination in example 6, 2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) was synthesized]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and (2S, 4R) -4-hydroxypyrrole-2-carboxylic acid to synthesize (2S, 4R) -1- ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenol)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid. MS [. Sup.M+1 ]] + :657.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.60(d,J＝7.6Hz,1H),7.43(t,J＝7.6Hz,1H),7.29–7.16(m,2H),6.98(d,J＝8.2Hz,1H),6.70(d,J＝7.6Hz,1H),5.55–5.45(m,2H),4.17–3.99(m,3H),3.87(s,6H),3.75–3.65(m,2H),3.60–3.51(m,4H),3.24–3.10(m,2H),2.46(t,J＝7.1Hz,2H),2.40–2.26(m,5H),1.97–1.70(m,7H)。
Example 10
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-alanine
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
preparation of ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-alanine:
With reference to the synthetic method of reductive amination in example 6, 2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) was synthesized]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and L-alanine to synthesize ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-alanine. MS [. Sup.M+1 ]] + :614.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.60(d,J＝7.6Hz,1H),7.43(t,J＝7.6Hz,1H),7.29–7.17(m,2H),6.99(d,J＝8.2Hz,1H),6.70(d,J＝7.4Hz,1H),5.55–5.43(m,2H),4.17–3.98(m,2H),3.89(s,6H),3.69–3.62(m,2H),3.61–3.34(m,5H),2.51–2.43(m,2H),2.42–2.31(m,4H),1.94–1.82(m,5H),1.20(d,J＝6.6HZ,3H)。
Example 11
((2- ((2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
preparation of 1- (3- (3-bromo-2-methylphenoxy) propyl) -4-methylpiperazine:
to the reaction flask was added 3-bromo-2-methylphenol (2.82 g,1 eq), 1- (3-chloropropoxy) -4-methylpiperazine (2.91 g,1.1 eq), acetonitrile (60 mL), potassium carbonate (6.24 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (250 mL), extracted with ethyl acetate (100 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and the crude silica gel column chromatographed to give 1- (3- (3-bromo-2-methylphenoxy) propyl) -4-methylpiperazine (3.69 g, yield: 76%). MS [. Sup.M+1 ] +:327.1/329.1.
Preparation of 1-methyl-4- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperazine:
1- (3- (3-bromo-2-methylphenoxy) propyl) -4-methylpiperazine (3.69 g,1 eq), pinacol biborate (5.73 g,2 eq), potassium acetate (2.22 g,2 eq), pd (dppf) Cl were added to the reaction flask 2 (0.42 g,0.05 eq) and 1, 4-dioxane (150 mL). The reaction was stirred for two hours with nitrogen protection at 90 ℃ and stirred for characterization of complete reaction, quenched by water (850 mL), extracted with ethyl acetate (200 mL x 3), combined organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, suction filtered, concentrated and crude silica gel column chromatographed to give 1-methyl-4- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperazine (2.25 g, yield: 53%). MS [. Sup.M+1 ]]+:374.3/376.3.
Preparation of methyl-2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propyl) - [1,1' -biphenyl ] -3-carboxylic acid ester:
1-methyl-4- (3- (2-methyl-3- (4, 5-tetramethyl)) was added to the reaction flask-1,3, 2-dioxaborane-2-yl) phenoxy) propyl piperazine (0.75 g,1.2 eq), methyl 2-bromo-3-iodobenzoate (0.56 g,1 eq), potassium carbonate (0.68 g,3 eq), pd (dppf) Cl 2 (0.06 g,0.05 eq), toluene (50 mL), water (5 mL) and methanol (5 mL). Heating to 90 ℃ under nitrogen protection, stirring and reacting for 16 hours, LCMS characterizing complete reaction, stopping reaction, adding water (400 mL) to quench the system, extracting ethyl acetate (100 mL. 3), combining organic phases and washing with saturated saline once, drying with anhydrous sodium sulfate, suction filtering, concentrating, obtaining methyl-2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propyl) - [1,1' -biphenyl by crude silica gel column chromatography ]3-Formate (0.41 g, yield: 54%). MS [. Sup.M+1 ]]+:461.1/463.1
Preparation of (2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperidin-1-yl) propyl) - [1,1' -biphen-yl ] -3-yl) methanol:
to the reaction flask was added methyl-2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propyl) - [1,1' -biphenyl]3-Formate (0.41 g,1 eq), freshly distilled tetrahydrofuran (50 mL), and LiAlH was added in portions at 5 ℃ 4 (67.4 mg,2 eq) stirred at room temperature for 30min, TLC indicated that the reaction was complete, the reaction system was slowly added dropwise to saturated NH 4 Quenching the reaction in Cl aqueous solution, extracting with ethyl acetate (100 mL. Times.3), combining the organic phases, washing with saturated saline once, drying with anhydrous sodium sulfate, suction filtering, concentrating, and subjecting the crude product to silica gel column chromatography to obtain (2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperidin-1-yl) propyl) - [1,1' -biphenyl)]-3-yl) methanol (0.25 g, yield: 65%). MS [. Sup.M+1 ]]+:433.1/435.1.
Preparation of 2- ((2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propyl) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde:
to the reaction flask was added (2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperidin-1-yl) propyl) - [1,1' -biphenyl ] -3-yl) methanol (0.25 g,1 eq), 2-chloro-4, 6-dimethoxypyrimidine (0.17 g,1.5 eq), acetonitrile (30 mL), potassium carbonate (0.24 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (200 mL), extracted with ethyl acetate (50 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and the crude silica gel was chromatographed to give 2- ((2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propyl) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (287.3 mg, yield: 83%). MS [ M+1] +:599.2/602.2
Preparation of ((2- ((2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline:
2- ((2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propyl) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (60.1 mg,1 eq) and L-proline (34.5 mg,3 eq) were dissolved in a mixed solvent of DMF (5 mL) and methanol (2 mL), 1 drop of acetic acid was added dropwise with stirring, and after reaction at room temperature for 30 minutes, sodium cyanoborohydride (20.9 mg,3 eq) was added to the system. Stirring overnight at room temperature, LCMS indicated the reaction was complete, stopped, quenched with water (50 mL), extracted with ethyl acetate (20 mL x 3), combined organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and the crude product purified by preparative liquid phase to give (2- ((2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline (23.4 mg, yield: 33%). MS [. Sup.M+1 ] +:698.2/700.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.66(d,J＝7.2Hz,1H),7.48(t,J＝7.6Hz,1H),7.31–7.22(m,2H),7.01(d,J＝8.0Hz,1H),6.68(d,J＝7.2Hz,1H),5.58(s,2H),4.10–4.03(m,2H),3.95(s,6H),3.37–3.33(m,2H),3.23–3.17(m,1H),2.74–2.63(m,1H),2.47–2.24(m,9H),2.17(s,3H),2.12–2.05(m,1H),1.97(s,3H),1.90–1.64(m,6H)。
Example 12
((2- ((2-bromo-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphen yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
with reference to the synthetic method of example 11, ((2- ((2-bromo-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphenyl) is synthesized starting from tert-butyldimethylsilyl-protected 1- (3-chloropropyl) piperidin-4-ol]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :699.2/701.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.62(d,J＝7.2Hz,1H),7.48(t,J＝7.6Hz,1H),7.15-7.26(m,2H),6.99(d,J＝8.0Hz,1H),6.70(d,J＝7.4Hz,1H),5.59-5.43(m,2H),4.12–4.06(m,2H),3.95(s,6H),3.68–3.57(m,2H),3.25–3.18(m,1H),2.72–2.64(m,1H),2.47–2.27(m,8H),2.09–2.04(m,1H),1.95(s,3H),1.84–1.64(m,9H)。
Example 13
((2- ((2-chloro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The structural formula of the compound is as follows:
the synthesis method comprises the following steps:
preparation of 2- ((2-chloro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propyl) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-methoxypyrimidine-5-carbaldehyde:
1-methyl-4- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperazine (0.75 g,1.2 eq), 2- ((3-bromo-2-chlorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (0.65 g,1 eq), potassium carbonate (0.68 g,3 eq), pd (dppf)Cl 2 (0.06 g,0.05 eq), toluene (50 mL), water (5 mL) and methanol (5 mL). Heating to 90 ℃ under nitrogen protection, stirring for 16 hours, performing LCMS to characterize the reaction to be complete, stopping the reaction, adding water (400 mL) to quench the system, extracting ethyl acetate (100 mL of 3), combining organic phases, washing the organic phases with saturated saline once, drying the organic phases with anhydrous sodium sulfate, performing suction filtration, concentrating the organic phases, and performing silica gel column chromatography on the crude product to obtain 2- ((2-chloro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propyl) - [1,1' -biphenyl) ]-3-yl) methoxy) -4, 6-methoxypyrimidine-5-carbaldehyde (0.57 g, yield: 51%). MS [. Sup.M+1 ]]+:555.2/557.2。
Preparation of ((2- ((2-chloro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline:
2- ((2-chloro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propyl) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-methoxypyrimidine-5-carbaldehyde (55.5 mg,1 eq) and L-proline (34.5 mg,3 eq) were dissolved in a mixed solvent of DMF (5 mL) and methanol (2 mL), 1 drop of acetic acid was added dropwise with stirring, and after reaction at room temperature for 30 minutes, sodium cyanoborohydride (20.9 mg,3 eq) was added to the system. Stirring overnight at room temperature, LCMS indicated the reaction was complete, quenched the reaction by adding water (50 mL), extracted with ethyl acetate (20 mL x 3), combined organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and the crude product purified by preparative liquid phase to give (2- ((2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline (20.9 mg, yield: 32%). MS [. Sup.M+1 ] +:654.3/656.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.61(d,J＝7.2Hz,1H),7.44(t,J＝7.6Hz,1H),7.28–7.20(m,2H),6.98(d,J＝8.0Hz,1H),6.70(d,J＝7.2Hz,1H),5.53(s,2H),4.08–4.03(m,2H),3.91(s,6H),3.33–3.31(m,2H),3.23–3.19(m,1H),2.70–2.63(m,1H),2.47–2.27(m,9H),2.14(s,3H),2.09–2.04(m,1H),1.91–1.64(m,9H)。
Example 14
((2- ((2-chloro-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphen yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthesis method comprises the following steps:
preparation of 2- ((3 ' - (3- (4- ((tert-butyldimethylsilyl) oxy) piperidin-1-yl) propyl) -2-chloro-2 ' -methyl- [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde:
into a reaction flask was charged 4- ((tert-butyldimethyl) oxy) -1- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperidine (1.07 g,1.3 eq), 2- ((3-bromo-2-chlorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (0.65 g,1 eq), potassium carbonate (0.68 g,3 eq), pd (dppf) Cl 2 (0.06 g,0.05 eq), toluene (50 mL), water (5 mL) and methanol (5 mL). Heating to 90 ℃ under nitrogen protection, stirring for 16 hours, performing LCMS to characterize the reaction to be complete, stopping the reaction, adding water (400 mL) to quench the system, extracting ethyl acetate (100 mL of 3), combining organic phases, washing the organic phases with saturated saline once, drying the organic phases with anhydrous sodium sulfate, suction filtering, concentrating, and performing crude silica gel column chromatography to obtain 2- ((3 ' - (3- (4- ((tert-butyldimethylsilyloxy) piperidin-1-yl) propyl) -2-chloro-2 ' -methyl- [1,1' -biphenol) phenyl]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (0.51 g, yield: 45%). MS [. Sup.M+1 ]]+:670.3.
Preparation of (S) -1- ((2- ((3 ' - (3- (4- ((tert-butyldimethylsilyl) oxy) piperidin-1-yl) propyl) -2-chloro-2 ' -methyl- [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) pyrrolidinyl-2-carboxylic acid:
2- ((3 ' - (3- (4- ((tert-butyldimethylsilyloxy) piperidin-1-yl) propyl) -2-chloro-2 ' -methyl- [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (67.0 mg,1 eq) and L-proline (34.5 mg,3 eq) were dissolved in a mixed solvent of DMF (5 mL) and methanol (2 mL), 1 drop of acetic acid was added dropwise with stirring, and after 30 minutes of reaction at room temperature, sodium cyanoborohydride (20.9 mg,3 eq) was added to the system. Stirring overnight at room temperature, LCMS indicated that the reaction was complete, the reaction was stopped, the system was quenched with water (50 mL), ethyl acetate (20 mL. 3) was extracted, the organic phases were combined and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered with suction, concentrated, and the crude product was purified by preparative liquid phase to give (S) -1- ((2- ((3 ' - (3- (4- ((tert-butyldimethylsilyloxy) oxy) piperidin-1-yl) propyl) -2-chloro-2 ' -methyl- [1,1' -bipyridyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) pyrrolidinyl-2-carboxylic acid (34.5 mg, yield: 35%). MS [. Sup.M+1 ] +:769.4.
Preparation of ((2- ((2-chloro-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline:
(S) -1- ((2- ((3 ' - (3- (4- ((tert-butyldimethylsilyl) oxy) piperidin-1-yl) propyl) -2-chloro-2 ' -methyl- [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) pyrrolidinyl-2-carboxylic acid (34.5 mg,1 eq) was dissolved in ultra-dry tetrahydrofuran (2 mL), and a solution of tetra-n-butylammonium fluoride in tetrahydrofuran (TBAF, 1Min THF,0.13mL,3eq) was added dropwise to the system with stirring at room temperature. After stirring at room temperature for 2 hours, LCMS indicated complete reaction, stopped reaction, quenched with water (50 mL), extracted with ethyl acetate (20 mL x 3), combined organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and the crude product purified by preparative liquid phase to give ((2- ((2-chloro-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline (10.5 mg, yield: 35%). MS [. Sup.M+1 ] +:655.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.61(d,J＝7.2Hz,1H),7.43(t,J＝7.6Hz,1H),7.27-7.16(m,2H),6.98(d,J＝8.0Hz,1H),6.68(d,J＝7.4Hz,1H),5.56-5.41(m,2H),4.09–4.03(m,2H),3.91(s,6H),3.68–3.57(m,2H),3.25–3.17(m,1H),2.72–2.64(m,1H),2.47–2.27(m,8H),2.09–2.04(m,1H),1.95(s,3H),1.84–1.64(m,9H)。
Example 15
((2- ((2-fluoro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
((2- ((2-fluoro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
Preparation of 2- ((3-bromo-2-fluorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde:
to the reaction flask was added 3-bromo-2-fluorobenzyl alcohol (2.4 g,1 eq), 2-chloro-4, 6-dimethoxypyrimidine (3.6 g,1.5 eq), acetonitrile (100 mL), potassium carbonate (4.8 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (700 mL), extracted with ethyl acetate (200 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and crude silica gel column chromatographed to give 2- ((3-bromo-2-fluorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (3.0 g, yield: 70%). MS [. Sup.M+1 ] +:371.0/373.0.
Preparation of 2- ((2-fluoro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde:
4- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) morpholine (1.28 g,1.1 eq), 2- ((3-bromo-2-fluorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (1.18 g,1 eq), potassium carbonate (1.32 g,3 eq), pd (dppf) Cl 2 (0.12 g,0.05 eq), toluene (50 mL), water (5 mL) and methanol (5 mL). Heating to 90 ℃ under the protection of nitrogen, stirring and reacting for 16 hours, LCMS (liquid Crystal ms) characterizing complete reaction, stopping reaction, adding water (350 mL) to quench the system, extracting ethyl acetate (100 mL x 3), combining organic phases and washing with saturated saline once, drying with anhydrous sodium sulfate, suction filtering, concentrating, and performing crude silica gel column chromatography to obtain 2- ((2-fluoro-2 '-methyl-3')(3-morpholinopropoxy) - [1,1' -biphenylyl ]]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (0.69 g, yield: 41%). MS [. Sup.M+1 ]]+:526.2.
Preparation of ((2- ((2-fluoro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline:
2- ((2-fluoro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (52.5 mg,1 eq) and L-proline (34.5 mg,3 eq) were dissolved in a mixed solvent of DMF (5 mL) and methanol (2 mL), 1 drop of acetic acid was added dropwise with stirring, and after reaction at room temperature for 30min, sodium cyanoborohydride (20.9 mg,3 eq) was added to the system. Stirring overnight at room temperature, LCMS indicated the reaction was complete, quenched the reaction by adding water (50 mL), extracted with ethyl acetate (20 mL x 3), combined organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and the crude product purified by preparative liquid phase to give (2- ((2-bromo-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline (26.8 mg, yield: 43%). MS [. Sup.M+1 ] +:625.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.68(d,J＝7.2Hz,1H),7.43(t,J＝7.6Hz,1H),7.33–7.18(m,2H),7.01(d,J＝8.0Hz,1H),6.68(d,J＝7.2Hz,1H),5.59–5.52(m,2H),4.12–4.02(m,2H),3.95–3.78(m,8H),3.61–3.51(m,4H),3.23–3.05(m,4H),2.52–2.43(m,2H),2.40–2.20(m,4H),2.04–1.94(m,1H),1.97–1.63(m,7H)。
Example 16
((2- ((2-fluoro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
the synthetic method of reference example 15 was followed by reacting 1-methyl-4- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperazine with 2- ((3-bromo-2-fluorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde to give 2- ((2-chloro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propyl) - [1,1' -biphenyl ]]-3-yl) methoxy) -4, 6-methoxypyrimidine-5-carbaldehyde, then subjecting the aldehyde to reductive amination with L-proline to give ((2- ((2-fluoro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :638.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.65(d,J＝7.2Hz,1H),7.43(t,J＝7.6Hz,1H),7.28–7.21(m,2H),6.99(d,J＝8.0Hz,1H),6.69(d,J＝7.2Hz,1H),5.56–5.49(m,2H),4.08–4.03(m,2H),3.95(s,6H),3.30–3.28(m,2H),3.24–3.19(m,1H),2.74–2.63(m,1H),2.46–2.27(m,9H),2.15(s,3H),2.10–2.04(m,1H),1.91–1.64(m,9H)。
Example 17
((2- ((2-fluoro-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphen yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
with reference to the synthetic method of example 14, 4- ((tert-butyldimethylsilyl) oxy) -1- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperidine was reacted with 2- ((3-bromo-2-fluorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde to give 2- ((3 ' - (3- (4- ((tert-butyldimethylsilyl) oxy) piperidin-1-yl) propyl) -2-fluoro-2 ' -methyl- [1,1' -biphenyl) ]-3-yl) methoxyThe method comprises the steps of (S) -1- ((2- ((3 ' - (3- (4- ((tert-butyldimethylsilyl) oxy) piperidin-1-yl) propyl) -2-fluoro-2 ' -methyl- [1,1' -biphenyl) by reductive amination of 4, 6-dimethoxy pyrimidine-5-carbaldehyde and L-proline]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl-methyl-pyrrolidinyl-2-carboxylic acid and finally removing the TBS protecting group by TBAF to give ((2- ((2-fluoro-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphenyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :639.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.66(d,J＝7.2Hz,1H),7.47(t,J＝7.6Hz,1H),7.26-7.17(m,2H),7.01(d,J＝8.0Hz,1H),6.70(d,J＝7.4Hz,1H),5.55-5.48(m,2H),4.12–4.04(m,2H),3.95(s,6H),3.71–3.57(m,2H),3.25–3.14(m,1H),2.73–2.64(m,1H),2.48–2.26(m,8H),2.10–2.04(m,1H),1.95(s,3H),1.84–1.65(m,9H)。
Example 18:
((2- ((2-chloro-2 ' -methyl-3 ' - (2-morpholinoethoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
preparation of 4- (2- (3-bromo-2-methylphenoxy) ethyl) morpholine:
to the reaction flask was added 3-bromo-2-methylphenol (1.87 g,1 eq), 4- (2-chloroethyl) morpholine (1.64 g,1.1 eq), acetonitrile (50 mL), potassium carbonate (4.14 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (150 mL), extracted with ethyl acetate (60 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and crude silica gel column chromatographed to give 4- (2- (3-bromo-2-methylphenoxy) ethyl) morpholine (2.16 g, yield: 72%). MS [. Sup.M+1 ] +:300.1.
Preparation of 4- (2- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) ethyl) morpholine:
4- (2- (3-bromo-2-methylphenoxy) ethyl) morpholine (2.16 g,1 eq), pinacol biborate (3.65 g,2 eq), potassium acetate (1.41 g,2 eq), pd (dppf) Cl were added to the reaction flask 2 (0.26 g,0.05 eq) and 1, 4-dioxane (60 mL). The reaction was stirred for two hours with nitrogen protection at 90 ℃ and stirred for characterization of complete reaction, quenched system with water (350 mL), extracted with ethyl acetate (100 mL x 3), combined organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, suction filtered, concentrated and crude silica gel column chromatographed to give 4- (2- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) ethyl) morpholine (1.27 g, yield: 51%). MS [. Sup.M+1 ]]+:348.2.
Preparation of 2- ((2-chloro-2 ' -methyl-3 ' - (2-morpholinoethoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde:
to the reaction flask was added 4- (2- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) ethyl) morpholine (1.27 g,1.1 eq), 2- ((3-bromo-2-chlorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (1.29 g,1 eq), potassium carbonate (1.39 g,3 eq), pd (dppf) Cl 2 (0.12 g,0.05 eq), toluene (50 mL), water (5 mL) and methanol (5 mL). Heating to 90 ℃ under the protection of nitrogen, stirring and reacting for 16 hours, LCMS (liquid Crystal ms) characterizing complete reaction, stopping reaction, adding water (350 mL) to quench the system, extracting ethyl acetate (100 mL of 3), combining organic phases and washing the organic phases with saturated saline once, drying with anhydrous sodium sulfate, suction filtering, concentrating, and performing silica gel column chromatography on the crude product to obtain 2- ((2-chloro-2 ' -methyl-3 ' - (2-morpholinoethoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (0.93 g, yield: 53%). MS [. Sup.M+1 ]]+:528.2.
Preparation of ((2- ((2-chloro-2 ' -methyl-3 ' - (2-morpholinoethoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline:
with reference to the synthetic method of reductive amination in example 6, 2- ((2-chloro-2 ' -methyl-3 ' - (2-morpholinoethoxy) - [1,1' -biphenyl) was synthesized]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and L-proline to synthesize ((2- ((2-chloro-2 ' -methyl-3 ' - (2-morpholinoethoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :627.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.61(dd,J＝7.6,1.5Hz,1H),7.44(t,J＝7.6Hz,1H),7.28–7.18(m,2H),7.02(d,J＝8.1Hz,1H),6.71(d,J＝7.4Hz,1H),5.61–5.46(m,2H),4.21–4.02(m,2H),3.95–3.81(m,8H),3.63–3.56(m,4H),3.27(dd,J＝9.1,5.3Hz,1H),3.19–3.10(m,1H),2.75(t,J＝5.7Hz,2H),2.66–2.57(m,1H),2.52–2.47(m,3H),2.12–2.00(m,1H),1.87(s,3H),1.84–1.55(m,4H)。
Example 19:
((2- ((2-chloro-2 ' -methyl-3 ' - (3-piperidin-1-yl) propoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
preparation of 1- (3- (3-bromo-2-methylphenoxy) propyl) piperidine:
to the reaction flask was added 3-bromo-2-methylphenol (1.87 g,1 eq), 1- (3-chloropropyl) piperidine (1.78 g,1.1 eq), acetonitrile (50 mL), potassium carbonate (4.14 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (150 mL), extracted with ethyl acetate (60 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and crude silica gel column chromatographed to give 1- (3- (3-bromo-2-methylphenoxy) propyl) piperidine (2.15 g, yield: 69%). MS [. Sup.M+1 ] +:312.1.
Preparation of 1- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperidine:
1- (3- (3-bromo-2-methylphenoxy) propyl) piperidine (2.15 g,1 eq), pinacol biborate (3.51 g,2 eq), potassium acetate (1.35 g,2 eq), pd (dppf) Cl 2 (0.26 g,0.05 eq) and 1, 4-dioxane (60 mL). The reaction was stirred for two hours with nitrogen protection at 90 ℃ to characterize the reaction completion by LCMS, stopped, quenched with water (350 mL), extracted with ethyl acetate (100 mL x 3), combined organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, suction filtered, concentrated and column chromatographed on crude silica gel to give 1- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperidine (1.21 g, yield: 49%). MS [. Sup.M+1 ] ]+:360.2.
Preparation of 2- ((2-chloro-2 ' -methyl-3 ' - (3- (piperidin-1-yl) propyl) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde:
1- (3- (2-methyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperidine (1.21 g,1.2 eq), 2- ((3-bromo-2-chlorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (1.09 g,1 eq), potassium carbonate (1.16 g,3 eq), pd (dppf) Cl 2 (0.11 g,0.05 eq), toluene (50 mL), water (5 mL) and methanol (5 mL). Heating to 90 ℃ under nitrogen protection, stirring and reacting for 16 hours, LCMS characterizing complete reaction, stopping reaction, adding water (350 mL) to quench the system, extracting ethyl acetate (100 mL. Times.3), combining organic phases and washing with saturated saline once, drying with anhydrous sodium sulfate, suction filtering, concentrating, and performing silica gel column chromatography on the crude product to obtain 2- ((2-chloro-2 ' -methyl-3 ' - (3- (piperidin-1-yl) propyl) - [1,1' -biphenol)]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (0.81 g, yield: 53%). MS [. Sup.M+1 ]]+:540.2.
Preparation of ((2- ((2-chloro-2 ' -methyl-3 ' - (3-piperidin-1-yl) propoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline:
with reference to the synthetic method of reductive amination in example 6, 2- ((2-chloro-2 ' -methyl-3 ' - (3- (piperidin-1-yl) propyl) - [1,1' -biphenyl) was synthesized ]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and L-proline are synthesized to ((2- ((2-chloro-2 ' -methyl-3 ' - (3-piperidin-1-yl) propoxy) - [1,1' -biphenyl)]-3-yl) methoxy group-4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :639.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.61(d,J＝7.2Hz,1H),7.43(t,J＝7.6Hz,1H),7.30–7.18(m,2H),6.98(d,J＝8.0Hz,1H),6.68(d,J＝7.3Hz,1H),5.55(s,2H),4.11–4.03(m,2H),3.95–3.79(m,8H),3.21–3.05(m,4H),2.46–2.39(m,2H),2.35–2.28(m,4H),2.04–1.96(m,1H),1.97–1.45(m,13H)。
Example 20:
((2- ((2-chloro-2 ' -methyl-3 ' - (2- (piperidin-1-yl) ethoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
with reference to the synthesis of example 19, using 1- (2-chloroethyl) piperidine as a starting material, (2- ((2-chloro-2 ' -methyl-3 ' - (2- (piperidin-1-yl) ethoxy) - [1,1' -biphenyl) was synthesized according to the synthesis of example 19]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :624.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.61(d,J＝7.2Hz,1H),7.43(t,J＝7.6Hz,1H),7.30–7.18(m,2H),6.98(d,J＝8.0Hz,1H),6.68(d,J＝7.3Hz,1H),5.55(s,2H),4.11–4.03(m,2H),3.95–3.79(m,8H),3.32–3.15(m,4H),2.48–2.39(m,2H),2.38–2.28(m,4H),2.04–1.96(m,1H),1.97–1.45(m,11H)。
Example 21:
((2- ((2-chloro-3 '- (3-piperidinepropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxy pyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
with reference to the synthesis of example 19, 3-bromo-phenol was used as starting material and ((2- ((2-chloro-3 '- (3-piperidylpropoxy) - [1,1' -biphenyl) was synthesized according to the synthesis of example 19]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ] ] + :627.3.
1 H-NMR(400MHz,d 6 -DMSO)δ7.62(dd,J＝7.6,1.8Hz,1H),7.45(t,J＝7.6Hz,1H),7.42–7.33(m,2H),7.00–6.91(m,3H),5.54(s,2H),4.05(t,J＝6.4Hz,2H),3.91(s,6H),3.87(s,2H),3.59–3.51(m,4H),3.33–3.25(m,2H),3.23–3.14(m,2H),2.64(dd,J＝17.2,9.8Hz,1H),2.42(t,J＝7.1Hz,2H),2.39–2.31(m,4H),2.14–2.00(m,1H),1.96–1.51(m,3H)。
Example 22:
((2- ((2-chloro-3 ' - (3- (dimethylamino) propoxy) -2' -methyl- [1,1' -biphen-yl ] -3-yl) methoxy-4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
with reference to the synthesis of example 19, using 3-chloro-N, N-dimethylpropyl-1-amine as starting material, ((2- ((2-chloro-3 ' - (3- (dimethylamino) propoxy) -2' -methyl- [1,1' -biphenyl) was synthesized according to the synthesis of example 19]-3-yl) methoxy-4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :599.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.60(d,J＝7.2Hz,1H),7.43(t,J＝7.6Hz,1H),7.29–7.18(m,2H),6.99(d,J＝8.0Hz,1H),6.70(d,J＝7.2Hz,1H),5.55(s,2H),4.11–4.03(m,2H),3.95(s,6H),3.91–3.79(m,2H),3.21–3.05(m,4H),2.46–2.39(m,4H),2.35–2.28(m,4H),2.04–1.96(m,1H),1.95–1.45(m,7H)。
Example 23:
((2- ((2, 2' -dichloro-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy-4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
preparation of 4- (3- (3-bromo-2-chlorophenoxy) propyl) piperidine:
to the reaction flask was added 3-bromo-2-chlorophenol (2.07 g,1 eq), 1- (3-chloropropyl) piperidine (1.78 g,1.1 eq), acetonitrile (50 mL), potassium carbonate (4.14 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (150 mL), extracted with ethyl acetate (60 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and crude silica gel column chromatographed to give 4- (3- (3-bromo-2-chlorophenoxy) propyl) piperidine (2.31 g, yield: 69%). MS [. Sup.M+1 ] +:334.0.
Preparation of 4- (3- (2-chloro-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperidine:
into a reaction flask was charged 4- (3- (3-bromo-2-chlorophenoxy) propyl) piperidine (2.31 g,1 eq), pinacol biborate (3.51 g,2 eq), potassium acetate (1.35 g,2 eq), pd (dppf) Cl 2 (0.26 g,0.05 eq) and 1, 4-dioxane (60 mL). Heating to 90deg.C under nitrogen protection, stirring for two hr, LCMS characterization, stopping the reaction, adding water (350 mL), quenching, extracting with ethyl acetate (100 mL×3), mixing the organic phases, and washing with saturated salineOnce, dry over anhydrous sodium sulfate, suction filtration, concentration, crude silica gel column chromatography gave 4- (3- (2-chloro-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperidine (1.29 g, yield: 49%). MS [. Sup.M+1 ]]+:382.2.
Preparation of 2- ((2, 2' -chloro-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde:
to the reaction flask was added 4- (3- (2-chloro-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperidine (1.29 g,1.2 eq), 2- ((3-bromo-2-chlorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (1.09 g,1 eq), potassium carbonate (1.16 g,3 eq), pd (dppf) Cl 2 (0.11 g,0.05 eq), toluene (50 mL), water (5 mL) and methanol (5 mL). Heating to 90 ℃ under the protection of nitrogen, stirring and reacting for 16 hours, LCMS (liquid Crystal ms) characterizing complete reaction, stopping reaction, adding water (350 mL) to quench the system, extracting ethyl acetate (100 mL of 3), combining organic phases and washing the organic phases with saturated saline once, drying with anhydrous sodium sulfate, suction filtering, concentrating, and performing silica gel column chromatography on the crude product to obtain 2- ((2, 2' -chloro-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) ]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (1.00 g, yield: 53%). MS [. Sup.M+1 ]]+:562.2.
Preparation of ((2- ((2, 2' -dichloro-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy-4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline:
with reference to the synthetic method of reductive amination in example 6, 2- ((2, 2' -chloro-3 ' - (3-morpholinopropoxy) - [1,1' -biphenylyl) is reacted]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and L-proline to synthesize ((2- ((2, 2' -dichloro-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl)]-3-yl) methoxy-4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :661.2.
1 H NMR(400MHz,d 6 -DMSO)δ7.63(dd,J＝7.6,1.4Hz,1H),7.46(t,J＝7.6Hz,1H),7.37(t,J＝8.0Hz,1H),7.30(dd,J＝7.6,1.5Hz,1H),7.23–7.19(m,1H),6.88(dd,J＝7.6,1.1Hz,1H),5.60–5.47(m,2H),4.22–4.09(m,2H),3.88(s,6H),3.80(d,J＝13.0Hz,1H),3.63(d,J＝12.8Hz,1H),3.60–3.50(m,4H),3.02–2.94(m,2H),2.46(t,J＝7.1Hz,2H),2.42–2.30(m,5H),2.01–1.86(m,3H),1.81–1.67(m,1H),1.66–1.56(m,2H)。
Example 24:
((2- ((2-chloro-2 ' -ethyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
/>
preparation of 4- (3- (3-bromo-2-ethylphenoxy) propyl) morpholine:
to the reaction flask was added 3-bromo-2-ethylphenol (2.01 g,1 eq), 1- (3-chloropropyl) piperidine (1.78 g,1.1 eq), acetonitrile (50 mL), potassium carbonate (4.14 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (150 mL), extracted with ethyl acetate (60 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and crude silica gel column chromatographed to give 4- (3- (3-bromo-2-ethylphenoxy) propyl) morpholine (2.36 g, yield: 72%). MS [. Sup.M+1 ] +:328.1.
Preparation of 4- (3- (2-ethyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) morpholine:
4- (3- (3-bromo-2-ethylphenoxy) propyl) morpholine (2.36 g,1 eq), pinacol biborate (3.65 g,2 eq), potassium acetate (1.41 g,2 eq), pd (dppf) Cl were added to the reaction flask 2 (0.26 g,0.05 eq) and 1, 4-dioxane (60 mL). The reaction was stirred for two hours with nitrogen protection at 90 ℃ and stirred for characterization of complete reaction, quenched by water (350 mL), extracted with ethyl acetate (100 mL x 3), combined organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, suction filtered, concentrated and column chromatographed on crude silica gel to give 4- (3- (2-ethyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) morpholine (1.43 g, 53% yield). MS [. M + ]1]+:376.2.
Preparation of 2- ((2-chloro-2 ' -ethyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde:
4- (3- (2-Ethyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) morpholine (1.43 g,1.2 eq), 2- ((3-bromo-2-chlorobenzyl) oxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (1.23 g,1 eq), potassium carbonate (1.31 g,3 eq), pd (dppf) Cl 2 (0.12 g,0.05 eq), toluene (50 mL), water (5 mL) and methanol (5 mL). Heating to 90 ℃ under the protection of nitrogen, stirring and reacting for 16 hours, LCMS (liquid Crystal ms) characterizing the reaction to be complete, stopping the reaction, adding water (350 mL) to quench the system, extracting ethyl acetate (100 mL of 3), combining organic phases and washing the organic phases with saturated saline once, drying with anhydrous sodium sulfate, suction filtering, concentrating, and obtaining 2- ((2-chloro-2 ' -ethyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) by crude silica gel column chromatography]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde (0.87 g, yield: 49%). MS [. Sup.M+1 ]]+:556.2.
Preparation of ((2- ((2-chloro-2 ' -ethyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline:
with reference to the reductive amination synthesis of example 6, 2- ((2-chloro-2 ' -ethyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenylyl) was synthesized]-3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde and L-proline to synthesize ((2- ((2-chloro-2 ' -ethyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :655.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.61(d,J＝7.2Hz,1H),7.43(t,J＝7.6Hz,1H),7.28–7.18(m,2H),6.98(d,J＝8.0Hz,1H),6.68(d,J＝7.2Hz,1H),5.52(s,2H),4.12–4.02(m,2H),3.95(s,6H),3.91–3.78(m,2H),3.61–3.50(m,4H),3.23–3.08(m,4H),2.51–2.43(m,2H),2.40–2.30(m,4H),2.04–1.97(m,3H),1.95–1.55(m,4H),1.35–1.25(m,3H)。
Example 25:
((2- ((2-chloro-2 ' -isopropyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
with reference to the synthesis of example 23, 3-bromo-2-isopropyl-phenol was used as starting material, and ((2- ((2-chloro-2 ' -isopropyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) was synthesized according to the synthesis of example 23]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :669.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.60(d,J＝7.2Hz,1H),7.44(t,J＝7.6Hz,1H),7.30–7.17(m,2H),6.99(d,J＝7.6Hz,1H),6.70(d,J＝7.2Hz,1H),5.60–5.49(m,2H),4.10–4.02(m,2H),3.95(s,6H),3.91–3.78(m,2H),3.61–3.50(m,4H),3.23–3.08(m,4H),2.51–2.43(m,2H),2.40–2.30(m,4H),2.04–1.97(m,2H),1.95–1.55(m,4H),1.35–1.24(m,6H)。
Example 26:
((2- ((2-chloro-2 ' -cyclopropyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
with reference to the synthesis of example 23, 3-bromo-2-cyclopropyl-phenol was used as starting material, and ((2- ((2-chloro-2 ' -cyclopropyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) was synthesized according to the synthesis of example 23]-3-yl)Methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :667.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.60(d,J＝7.2Hz,1H),7.44(t,J＝7.6Hz,1H),7.30–7.17(m,2H),6.99(d,J＝7.6Hz,1H),6.70(d,J＝7.2Hz,1H),5.60–5.49(m,2H),4.10–4.02(m,2H),3.95–3.78(m,8H),3.60–3.50(m,4H),3.23–3.08(m,4H),2.51–2.43(m,2H),2.40–2.30(m,4H),2.04–1.97(m,1H),1.95–1.55(m,5H),1.24–0.99(m,4H)。
Example 27:
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4- ((3-cyanobenzyl) oxy) -6-methoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
preparation of 3- (((2-chloro-6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile:
sodium hydrogen (1.21 g,1.5eq,60% purity) was added to a solution of 3-hydroxymethylbenzonitrile (2.66 g,1 eq) in DMF (50 mL) with stirring at 0deg.C. After stirring at 0 ℃ for 0.5 hours, a DMF solution of 2, 4-dichloro-6-methoxypyrimidine (3.58 g,1 eq) was added dropwise to the reaction system, the reaction was warmed to room temperature under nitrogen protection, LCMS was stirred for two hours to characterize the reaction to completion, the reaction was stopped, the system was quenched with water (500 mL), ethyl acetate (200 mL x 3) was extracted, the organic phases were combined and washed once with saturated brine, dried over anhydrous sodium sulfate, suction filtered, concentrated, and crude silica gel column chromatography afforded 3- (((2-chloro-6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile (2.97 g, yield: 54%). MS [. Sup.M+1 ] +:276.0.
Preparation of 3- (((2- ((3-bromo-2-chlorobenzyloxy) oxy) -6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile:
to the reaction flask was added 3- (((2-chloro-6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile (2.97 g,1 eq), 3-bromo-2-chlorobenzyl alcohol (2.62 g,1.1 eq), acetonitrile (50 mL), potassium carbonate (4.46 g,3 eq). The temperature was raised to 70℃and the reaction was stirred for two hours. LCMS indicated completion of the reaction, stopped the reaction, quenched the system with water (250 mL), extracted with ethyl acetate (90 mL x 3), combined the organic phases and washed once with saturated brine, dried over anhydrous sodium sulfate, filtered off with suction, concentrated, and the crude silica gel column chromatographed to give 3- (((2- ((3-bromo-2-chlorobenzyloxy) oxy) -6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile (1.78 g, yield: 36%). MS [. Sup.M+1 ] +:460.0.
Preparation of 3- (((2- ((3-bromo-2-chlorobenzyloxy) oxy) -5-formyl-6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile:
phosphorus oxychloride (8.89 g,15 eq) was added dropwise to a reaction flask containing DMF (4.23 g,15 eq) in an ice-water bath, stirred for 30min in an ice-water bath, a solution of 3- (((2- ((3-bromo-2-chlorobenzyloxy) oxy) -6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile (1.78 g,1 eq) in DMF (20 mL) was added dropwise to the reaction system, and the reaction was stirred for two hours at 50 ℃. LCMS indicated complete reaction and stopped the reaction. The reaction was added dropwise to an ice-water bath under stirring, neutralized with sodium bicarbonate (ph=7), filtered with suction, washed twice with water, and the dried crude product was purified by silica gel column chromatography to give 3- (((2- ((3-bromo-2-chlorobenzyloxy) oxy) -5-formyl-6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile (0.87 g, yield 46%). MS [. Sup.M+1 ] ] + :488.0.
Preparation of 3- (((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -5-formyl-6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile:
to the reaction flask was added 4- (3- (2-chloro-3- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) phenoxy) propyl) piperidine (0.96 g,1.5 eq), 3- (((2- ((3-bromo-2-chlorobenzyloxy) oxy) -5-formyl-6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile (0.87 g,1 eq), potassium carbonate (0.74 g,3 eq), pd (dppf) Cl 2 (0.13 g,0.1 eq), toluene (50 mL), water (5 mL) and methanol (5 mL). Heating to 90deg.C under nitrogen protection, stirring for 16 hr, LCMS characterization, stopping reaction, adding water (350 mL), quenching system, extracting with ethyl acetate (100 mL×3), mixing organic phases, and adding saturated saltWashing with water once, drying with anhydrous sodium sulfate, suction filtering, concentrating, and subjecting the crude product to silica gel column chromatography to obtain 3- (((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) group)]-3-yl) methoxy) -5-formyl-6-methoxypyrimidin-4-yl) methyl benzonitrile (0.57 g, yield: 50%). MS [. Sup.M+1 ]]+:643.2.
Preparation of ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4- ((3-cyanobenzyl) oxy) -6-methoxypyrimidin-5-yl) methyl) -L-proline:
With reference to the reductive amination synthesis of example 6, 3- (((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) is synthesized]-3-yl-methoxy) -5-formyl-6-methoxypyrimidin-4-yl) oxy) methyl) benzonitrile and L-proline to synthesize ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4- ((3-cyanobenzyl) oxy) -6-methoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :743.3.
1 H NMR(400MHz,d 6 -DMSO)δ8.19(s,1H),8.03–7.99(m,1H),7.69–7.60(m,2H),7.53–7.43(m,2H),7.32–7.20(m,2H),7.00(d,J＝8.0Hz,1H),6.68(d,J＝7.2Hz,1H),5.60–5.40(m,4H),4.08–4.00(m,2H),3.95–3.78(m,5H),3.60–3.50(m,4H),3.20–3.05(m,4H),2.50–2.43(m,2H),2.40–2.30(m,4H),2.04–1.96(m,1H),1.97–1.75(m,6H),1.73–1.65(m,1H)。
Example 28:
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4-methoxy-6- (pyridin-3-ylmethoxy) pyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
with reference to the synthesis method of example 26, 3-hydroxymethylpyridine was used asStarting material synthesis ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl)]-3-yl) methoxy) -4-methoxy-6- (pyridin-3-ylmethoxy) pyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :718.3.
1 H NMR(400MHz,d 6 -DMSO)δ8.78(d,J＝1.6Hz,1H),8.58(dd,J＝4.8,1.6Hz,1H),7.98(d,J＝8.0Hz,1H),7.69–7.60(m,2H),7.48–7.43(m,1H),7.32–7.20(m,2H),7.00(d,J＝8.0Hz,1H),6.68(d,J＝7.2Hz,1H),5.60–5.40(m,4H),4.12–4.04(m,2H),4.01–3.78(m,5H),3.60–3.50(m,4H),3.20–3.05(m,4H),2.50–2.43(m,2H),2.40–2.30(m,4H),2.04–1.96(m,1H),1.97–1.55(m,7H)。
Example 29
(2S, 4R) -1- ((2- ((2-bromo- [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid
The synthetic route is as follows:
preparation of (2 s,4 r) -1- ((2- ((2-bromo- [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid:
2- ((2-bromo- [1,1 '-biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidine-5-carbaldehyde was reacted with L-hydroxyproline to synthesize (2 s,4 r) -1- ((2- ((2-bromo- [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid.
MS:[M+1] + :544.1/546.1。
1 H NMR(400MHz,d 6 -DMSO)δ7.60(dd,J＝7.6,1.6Hz,1H),7.54-7.31(m,7H),5.53(s,2H),4.94(s,1H),4.22-4.11(m,1H),3.96-3.74(m,8H),3.37(t,J＝8.0Hz,2H),3.28-3.24(m,1H),1.91-1.80(m,2H)。
Example 30:
((2- ((2-chloro-2 ' -butyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline
The synthetic route is as follows:
with reference to the synthesis of example 23, 3-bromo-2-butyl-phenol was used as starting material, and ((2- ((2-chloro-2 ' -butyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl) was synthesized according to the synthesis of example 23]-3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline. MS [. Sup.M+1 ]] + :683.3.
1 H NMR(400MHz,d 6 -DMSO)δ7.61(d,J＝7.2Hz,1H),7.45(t,J＝7.6Hz,1H),7.31–7.18(m,2H),7.00(d,J＝7.6Hz,1H),6.71(d,J＝7.2Hz,1H),5.62–5.50(m,2H),4.12–4.05(m,2H),3.96(s,6H),3.92–3.80(m,2H),3.61–3.50(m,4H),3.24–3.11(m,4H),2.61–2.47(m,3H),2.40–2.30(m,4H),2.07–1.55(m,8H),1.37–1.24(m,2H),0.91–0.85(m,3H)。
Detecting the inhibitory effect of a compound on the binding of PD-1/PD-L1 proteins to each other
In vitro kinase level was measured using the PD1/PD-L1 binding assay kits assay kit from Cisbio.
Screening principle and method of PD-1/PD-L1 small molecule inhibitor:
1) Principle of: PD-L1 protein has Tag1 (Tag 1 is a common Tag of purified protein), PD-1 protein has Tag2 (Tag 2 is a common Tag of purified protein), and anti-Tag1 antibody marked by Eu and anti-Tag2 antibody marked by XL665 are respectively combined with the two Tag proteins. When excited by a laser, energy is transferred from the donor Eu to the acceptor XL665, causing the XL665 to emit light. After addition of the inhibitor, the binding of PD-1 and PD-L1 is blocked, so that Eu is far away from XL665, which will affect the fluorescence energy transfer, and the signal will be reduced. The blocking of the binding of the inhibitor to PD-L1 and PD-1 is judged by the change in the intensity of the signal.
2) The method comprises the following steps: specific experimental protocols can be found in the PD1/PD-L1 binding kit instructions 62ICP01PEG and 64ICP01PEH from Cisbio. The simple description is as follows: taking a new 384-well ELISA plate, adding 2 mu L of diluent or target compounds with different concentrations diluted by the diluent into each well, then adding 4 mu L of PD-1 protein and 4 mu L of PD-L1 protein, and incubating for 15min at normal temperature. To each well, 10. Mu.L of a mixture of anti-Tag1-Eu and anti-Tag2-XL665 was added, and after incubation at room temperature for 2 hours, fluorescence signals of 620nM and 665nM were detected with an ELISA reader. The calculation formula of the signal proportion is as follows: (665 nM signal value)/(620 nM signal value). Times.10 4 . Each compound adopts 8-10 concentration gradients, three compound holes are arranged at each concentration, and the obtained result is subjected to nonlinear fitting by GraphPad Prism software to obtain the IC50 value of the compound.
TABLE 1 IC50 values for the compounds of the invention
/>
Note that: letter A represents an IC50 of less than 10nM;
letter B represents an IC50 between 10-100 nM;
letter C represents an IC50 of greater than 100nM.
The results in Table 1 show that the compounds of the present invention are effective in inhibiting the binding of PD-1/PD-L1 at various concentrations and are therefore useful in the treatment of diseases resulting from the binding of PD-1/PD-L1.
The invention provides a novel PD-1/PD-L1 small molecule inhibitor, and a pharmaceutical activity test result shows that the compound has excellent activity and is hopeful to become the novel PD-1/PD-L1 small molecule inhibitor.
In addition, fromAs can be seen in Table 1, relative to R 1 And R is R 2 Compounds of the invention which are long-chain groups, the compounds of the invention being based on R 1 And R is R 2 Forms a cyclic structure (or is a short chain structure) together with the nitrogen atom, limits partial conformation, has better directionality, has stronger binding force with PD-L1, and shows higher activity.

Claims (7)

1. A compound, characterized in that it is selected from any one of the following compounds:
(S) -1- ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) piperidine-2-carboxylic acid;
((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline;
((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-serine;
(2 s,4 r) -1- ((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid;
((2- ((2-bromo-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-alanine;
(S) -1- ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) piperidine-2-carboxylic acid;
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline;
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-serine;
(2 s,4 r) -1- ((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -4-hydroxypyrrole-2-carboxylic acid;
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-alanine;
((2- ((2-chloro-2 ' -methyl-3 ' - (3- (4-methylpiperazin-1-yl) propoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline;
((2- ((2-chloro-3 ' - (3- (4-hydroxypiperidin-1-yl) propoxy) -2' -methyl- [1,1' -biphen yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline;
((2- ((2-chloro-2 ' -methyl-3 ' - (3-piperidin-1-yl) propoxy) - [1,1' -biphen-yl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline;
((2- ((2, 2' -dichloro-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy-4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline;
((2- ((2-chloro-2 ' -ethyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline;
((2- ((2-chloro-2 ' -isopropyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline;
((2- ((2-chloro-2 ' -cyclopropyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4, 6-dimethoxypyrimidin-5-yl) methyl) -L-proline;
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4- ((3-cyanobenzyl) oxy) -6-methoxypyrimidin-5-yl) methyl) -L-proline;
((2- ((2-chloro-2 ' -methyl-3 ' - (3-morpholinopropoxy) - [1,1' -biphenyl ] -3-yl) methoxy) -4-methoxy-6- (pyridin-3-ylmethoxy) pyrimidin-5-yl) methyl) -L-proline.
2. A method of preparing the compound of claim 1, wherein the compound is the compound of claim 1; the method comprises the following reaction routes:
the method comprises the following steps:
(1) Dissolving SM1 and SM2 in a solvent 1, adding an alkaline reagent, and reacting at a temperature ranging from room temperature to 70 ℃ to obtain a compound C01;
(2) Dissolving a compound C01 and pinacol diboronate in a solvent 2, adding an alkaline reagent and a palladium metal catalyst, and reacting at a temperature range of 70-120 ℃ to obtain a compound C02;
(3) Dissolving a compound C02 and SM3 in a solvent 3, adding an alkaline reagent and palladium metal, and reacting the catalyst at a temperature of between 70 and 120 ℃ to obtain a compound C03;
(4) C03 and SM4 are dissolved in a solvent 4 to carry out reductive amination reaction to obtain a compound of the formula I;
in step (1), the solvent 1 is selected from one or more of tetrahydrofuran, DMSO, DMF, acetonitrile; the alkaline reagent is selected from one or more of cesium carbonate, potassium carbonate, sodium carbonate, potassium tert-butoxide and sodium tert-butoxide;
in the step (2), the solvent 2 is selected from one or more of 1, 4-dioxane, toluene and benzene; the alkaline reagent is selected from one or more of potassium acetate, cesium carbonate, potassium carbonate and sodium carbonate; the palladium metal catalyst is selected from Pd (PPh) 3 ) 4 、Pd(dppf)Cl 2 Palladium acetate, pd 2 (dba) 3 One or more of the following;
in step (3), the solvent 3 is selected from one or more of 1, 4-dioxane, toluene, methanol, and water; the alkaline reagent is selected from one or more of cesium carbonate, potassium carbonate, sodium carbonate, potassium tert-butoxide and sodium tert-butoxide; the palladium metal catalyst is selected from Pd (PPh) 3 ) 4 、Pd(dppf)Cl 2 Palladium acetate, pd 2 (dba) 3 One or more of the following;
in step (4), the solvent 4 is selected from tetrahydrofuran, DMSO, DMF, acetonitrileOne or more of methanol, dichloromethane; the reducing agent for the reductive amination reaction is selected from NaBH 3 CN, sodium triacetoxyborohydride, sodium borohydride.
3. A pharmaceutical composition comprising the compound or a pharmaceutically salt of the compound of claim 1 as an active ingredient, and a pharmaceutically acceptable carrier.
4. A pharmaceutical composition according to claim 3, wherein the pharmaceutical composition is in the form of an oral formulation or an injectable formulation.
5. Use of a compound or a pharmaceutically salt of a compound as claimed in claim 1 or a pharmaceutical composition as claimed in claim 3 in the manufacture of a medicament for the treatment of a disease associated with the PD-1/PD-L1 signaling pathway.
6. The use according to claim 5, wherein the disease is cancer or an immune disease.
7. The use of claim 6, wherein the cancer is selected from skin cancer, lung cancer, hematological tumor, breast cancer, glioma, digestive system tumor, reproductive system tumor, lymphoma, nervous system tumor, head and neck cancer; the immune disease is selected from myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus and dermatitis.
CN202011041992.4A 2020-09-28 2020-09-28 Compound as small molecule immunosuppressant, preparation method and application thereof Active CN114276328B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011041992.4A CN114276328B (en) 2020-09-28 2020-09-28 Compound as small molecule immunosuppressant, preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011041992.4A CN114276328B (en) 2020-09-28 2020-09-28 Compound as small molecule immunosuppressant, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN114276328A CN114276328A (en) 2022-04-05
CN114276328B true CN114276328B (en) 2023-09-01

Family

ID=80868167

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011041992.4A Active CN114276328B (en) 2020-09-28 2020-09-28 Compound as small molecule immunosuppressant, preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114276328B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368090A (en) * 2015-10-15 2018-08-03 百时美施贵宝公司 Compound as immunomodulator
CN108698995A (en) * 2016-01-08 2018-10-23 格罗宁根大学 The inhibitor of PD-1/PD-L1 albumen/protein-interacting
WO2019174533A1 (en) * 2018-03-13 2019-09-19 广东东阳光药业有限公司 Small molecule pd-1/pd-l1 inhibitor and use thereof in drugs
WO2019191624A1 (en) * 2018-03-29 2019-10-03 Arbutus Biopharma, Inc. Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
CN111386265A (en) * 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
WO2020156323A1 (en) * 2019-01-31 2020-08-06 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368090A (en) * 2015-10-15 2018-08-03 百时美施贵宝公司 Compound as immunomodulator
CN108698995A (en) * 2016-01-08 2018-10-23 格罗宁根大学 The inhibitor of PD-1/PD-L1 albumen/protein-interacting
CN111386265A (en) * 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
WO2019174533A1 (en) * 2018-03-13 2019-09-19 广东东阳光药业有限公司 Small molecule pd-1/pd-l1 inhibitor and use thereof in drugs
WO2019191624A1 (en) * 2018-03-29 2019-10-03 Arbutus Biopharma, Inc. Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
WO2020156323A1 (en) * 2019-01-31 2020-08-06 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof

Also Published As

Publication number Publication date
CN114276328A (en) 2022-04-05

Similar Documents

Publication Publication Date Title
CN109400522B (en) Compound with PD-L1 inhibition activity, preparation method and application thereof
AU2019348094B2 (en) Isoindoline compound, preparation method, pharmaceutical composition and use thereof
CA3177261A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
US11352352B2 (en) Aminopyrimidine compound, preparation method therefor and use thereof
CN113286794A (en) KRAS mutein inhibitors
CN112920180A (en) Glutaminase inhibitors
CN111344290A (en) Macrocyclic compound as Wee1 inhibitor and application thereof
JP2022502362A (en) Antibacterial compound
US11014943B2 (en) Azetidine derivative
CN114787142A (en) Compounds as cyclin-dependent kinase 9 inhibitors and uses thereof
KR20150052419A (en) Biguanide compounds and use thereof
CN102911157B (en) (E)-3-[2-bromo-5-(3-substituted propoxy)]phenyl-N-{4-methyl-3-[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl acrylamide compound
AU2020255702A1 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
CN114276328B (en) Compound as small molecule immunosuppressant, preparation method and application thereof
CN114957224B (en) EGFR inhibitor for tumor hypoxia targeting and application thereof
CN114269736B (en) Amide compound, pharmaceutical composition and application thereof
JP2024516194A (en) Compounds as PD1/PD-L1 inhibitors and methods thereof
CN113582971B (en) Small molecule immunosuppressant, preparation method and application thereof
CN116390923A (en) Heterocyclic derivative and preparation method and application thereof
JP2023526548A (en) Novel tricyclic aromatic heterocyclic compound and its preparation method, pharmaceutical composition and application
CN115381824A (en) Use of cyclin-dependent kinase 9 inhibitors
CN117143176A (en) Compounds for degrading SOS1 protein and application thereof
CN103328446A (en) Novel 4-amino-n-hydroxy-benzamides for the treatment of cancer
CN117551078A (en) Aromatic monocyclic derivative and preparation method and application thereof
WO2023179567A1 (en) Pyrimido-pyridazinone compound as toll-like receptor agonist

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant